StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
EWTXEdgewise Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$39.30▲ 0.03%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.23BShares out 1.100M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

9
  • 10.2After-hours26.10.03 05:47
    4Ownership#●●●#●●●

    Edgewise Therapeutics, Inc.

    Jonathan C. Fox, an executive at Edgewise Therapeutics, reported a change in his beneficial ownership of company securities as of October 1, 2026. This filing is a Form 4 statement disclosing the insider's updated share holdings.…more

    $39.30+0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 8.17After-hours26.08.18 07:41
    4/AOwnership

    Edgewise Therapeutics, Inc.

    Edgewise Therapeutics insider Michael Nofi has filed a Form 4/A amendment regarding a change in beneficial ownership reported on August 12, 2026. This filing serves as an administrative correction to the previously reported equity transaction details.…more

    $39.30+0.03%vs prev close
    View filingShare
  • 8.17After-hours26.08.18 07:41
    4/AOwnership

    Edgewise Therapeutics, Inc.

    Director Joanne M. Donovan of Edgewise Therapeutics has filed a Power of Attorney appointing Kevin Koch, R. Michael Carruthers, and John R. Moore as her attorneys-in-fact. These individuals are authorized to complete and file all required Section 16 forms, including Forms 3, 4, and 5, with the SEC effective May 3, 2021.…more

    $39.30+0.03%vs prev close
    View filingShare

8 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.8Pre-market26.10.08 21:07
    #●●●#●●●#●●●

    Edgewise Therapeutics Doses First Patient in Phase 2 HFpEF Study

    Edgewise Therapeutics has initiated the Phase 2 EQUINOX-HFpEF clinical trial by dosing the first patient with EDG-15400. This study evaluates the efficacy of the drug in adults suffering from symptomatic heart failure with preserved ejection fraction.…more

    $39.30+0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.22Pre-market26.09.22 20:10

    ●●●●●●●● ●●●●● ●●●●●●

    Edgewise Therapeutics announced that preclinical data for its hypertrophic cardiomyopathy candidate EDG-7500 shows improved cardiac relaxation while maintaining pumping function. This remains an early-stage development milestone requiring further clinical validation.…more

    $39.30+0.03%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →